113 related articles for article (PubMed ID: 38096698)
21. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
[TBL] [Abstract][Full Text] [Related]
22. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01).
Kim JH; Lee DE; Lee Y; Ha HI; Chang YJ; Chang SJ; Park SY; Lim MC
J Gynecol Oncol; 2022 Jul; 33(4):e54. PubMed ID: 35712968
[TBL] [Abstract][Full Text] [Related]
23. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
[TBL] [Abstract][Full Text] [Related]
24. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
[TBL] [Abstract][Full Text] [Related]
25. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience.
Valenzuela CD; Levine EA; Mangieri CW; Gawdi R; Moaven O; Russell G; Lundy ME; Perry KC; Votanopoulos KI; Shen P
Ann Surg Oncol; 2022 Jun; 29(6):3436-3445. PubMed ID: 35286531
[TBL] [Abstract][Full Text] [Related]
26. Feasibility of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced peritoneal surface tumors during the COVID-19 pandemic: A single-institution experience.
Radomski SN; Florissi I; Khan H; Siddiqi A; Paneitz DC; Johnston FM; Greer JB
J Surg Oncol; 2022 Dec; 126(8):1375-1382. PubMed ID: 36081374
[TBL] [Abstract][Full Text] [Related]
27. Long-term Quality of Life After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei: A Prospective Longitudinal Study.
Stearns AT; Malcomson L; Punnett G; Abudeeb H; Aziz O; Selvasekar CR; Fulford PE; Wilson MS; Renehan AG; O'Dwyer ST
Ann Surg Oncol; 2018 Apr; 25(4):965-973. PubMed ID: 29313146
[TBL] [Abstract][Full Text] [Related]
28. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M
World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771
[TBL] [Abstract][Full Text] [Related]
29. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis.
Hajjar R; Mercier F; Passot G; Pasquer A; Gelli M; Levine EA; Villeneuve L; Poncet G; Walter T; Glehen O
Eur J Surg Oncol; 2022 Jul; 48(7):1626-1630. PubMed ID: 35418324
[TBL] [Abstract][Full Text] [Related]
30. Anastomotic leakage after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer.
Feenstra TM; Verberne CJ; Kok NF; Aalbers AGJ
Eur J Surg Oncol; 2022 Dec; 48(12):2460-2466. PubMed ID: 36096855
[TBL] [Abstract][Full Text] [Related]
31. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
[TBL] [Abstract][Full Text] [Related]
32. Hepatectomy for metachronous colorectal liver metastases following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a report of three cases.
Ito K; Takemura N; Inagaki F; Mihara F; Kurokawa T; Gohda Y; Kiyomatsu T; Yano H; Kokudo N
World J Surg Oncol; 2019 Jun; 17(1):99. PubMed ID: 31196097
[TBL] [Abstract][Full Text] [Related]
33. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
34. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
Bhagwandin SB; Naffouje S; Salti G
J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes.
Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S
Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754
[TBL] [Abstract][Full Text] [Related]
37. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant Chemotherapy Followed by Cytoreductive Surgery and HIPEC Improves Survival in Peritoneal Metastatic Gastric Cancer.
Akturk Esen S; Ozgun YM; Hasturk D; Ucar G; Bostanci EB; Sendur MAN; Uncu D
Oncology; 2023; 101(5):321-327. PubMed ID: 36809752
[TBL] [Abstract][Full Text] [Related]
39. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
[TBL] [Abstract][Full Text] [Related]
40. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
